Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Dec 15, 2018; 10(12): 505-515
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.505
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.505
Figure 1 Kaplan-Meier analysis of survival data.
A: The estimated median progression-free survival was 5.8 mo (95%CI: 3.7-7.9); B: The estimated median overall survival was 9.0 mo (95%CI: 6.4-11.6).
- Citation: Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515
- URL: https://www.wjgnet.com/1948-5204/full/v10/i12/505.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i12.505